Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

ABSTRACT:

Background

Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB).

Methods

Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR).

Results

CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA leve

SUBMITTER: McEvoy AC 

PROVIDER: S-EPMC6038195 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature